Aayushi Pratap

3 weeks ago | cen.acs.org | Aayushi Pratap

On a warm sunny April afternoon, the mood at Columbia University's campus in Manhattan's Morningside Heights neighborhood seemed high-spirited. Students enjoyed a college fair, jumping on trampolines set up on the lush center lawns. A student band performed amid a crowd eating cotton candy and basking in the spring sunshine.

1 month ago | cen.acs.org | Aayushi Pratap

In the world of drug discovery and clinical trials, drug formulation can make or break a product's success, yet its role often goes underappreciated, says Christine Allen, cofounder and CEO of Intrepid Labs, a Toronto-based start-up that has emerged from stealth. Her company has secured $11 million in preseed and seed funding to rethink drug formulation with the use of robotics and artificial intelligence (AI).

1 month ago | cen.acs.org | Aayushi Pratap

It's hard nowadays for any big company to distance itself from artificial intelligence and its subset, machine learning. Drug services firms are no exception. These technologies are slowly picking up momentum among contract development and manufacturing organizations (CDMOs) to innovate drug synthesis and automate quality control processes that humans have traditionally managed. It's hard nowadays for any big company to distance itself from artificial intelligence and its subset, machine learning.

1 month ago | cen.acs.org | Aayushi Pratap

President Donald J. Trump has signed an executive order that seeks to do what past presidents, including Trump himself in his previous administration, did not succeed in doing: increasing US production of drugs and pharmaceutical ingredients. The order, signed May 5, intends to lower regulatory barriers for companies looking to expand or set up new drug manufacturing facilities in the US.

2 months ago | cen.acs.org | Aayushi Pratap

The race to develop small-molecule alternatives to peptide-based weight-loss and antidiabetes drugs isn't over, but a leader and a laggard have emerged. Eli Lilly and Company, which already markets weight-loss and diabetes drugs that must be injected, is a step closer to introducing a once-daily pill for the same conditions.